Fermentation and Biotechnology Laboratories, Astellas Pharma Inc., 156 Nakagawara, Kiyosu, Aichi, Japan.
J Biosci Bioeng. 2010 Feb;109(2):138-44. doi: 10.1016/j.jbiosc.2009.07.019. Epub 2009 Aug 27.
Industrial-scale production of FR901379 (WF11899A), which is a novel echinocandin type of lipopeptide antibiotic produced by mutant strain M-7 from Coleophoma empetri F-11899 (FERM BP-2635), was demonstrated. In order to achieve high-level production in fermentor culture, the medium previously developed was modified, in which three types of organic nitrogen were replaced by ammonium sulfate and corn steep liquor. To eliminate increase in viscosity, carbon source was intermittently fed. The viscosity was reduced from 20,000 cP to less than 10,000 cP. The FULLZONE impeller was introduced in the fermentor culture for sufficient mixing. Mixing time was quite improved and high reproducibility was achieved. Surprisingly, the viscosity of the broth was reduced to 1000 cP in a 4 m(3) scale fermentor. When k(L)a was selected as an index for scale-up and industrial scale production using a 15 m(3) fermentor with the FULLZONE impeller was conducted, FR901379 production was successfully obtained at more than 50 U/mL, almost the same level as with the 0.03 m(3) and 4 m(3) fermentors. In addition, superior reproducibility was obtained, and 500-fold scale-up was successfully achieved.
工业规模生产 FR901379(WF11899A),这是一种新型的棘白菌素类脂肽抗生素,由 Coleophoma empetri F-11899(FERM BP-2635)的突变株 M-7 产生。为了在发酵罐培养中实现高水平生产,对先前开发的培养基进行了改良,其中三种有机氮源被硫酸铵和玉米浆代替。为了消除粘度增加,采用间歇进料的碳源。将粘度从 20000cP 降低到小于 10000cP。在发酵罐培养中引入 FULLZONE 搅拌器以充分混合。混合时间得到了显著改善,并且实现了高重现性。令人惊讶的是,在 4m³发酵罐中,将发酵液的粘度降低到 1000cP。当 k(L)a 被选为放大的指标,并使用 FULLZONE 搅拌器在 15m³发酵罐中进行工业规模生产时,FR901379 的产量超过 50U/mL,几乎与 0.03m³和 4m³发酵罐相同。此外,获得了优异的重现性,成功实现了 500 倍放大。